Acomplia
E874318
Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
brand name drug
ⓘ
pharmaceutical drug ⓘ |
| adverseEffect |
anxiety
ⓘ
depression ⓘ dizziness ⓘ insomnia ⓘ mood disorders ⓘ nausea ⓘ suicidal ideation ⓘ vomiting ⓘ |
| approvalYear | 2006 ⓘ |
| approvedBy | European Medicines Agency NERFINISHED ⓘ |
| ATCCode | A08AX01 ⓘ |
| chemicalClass | pyrazole derivative ⓘ |
| contraindication |
major depression
ⓘ
ongoing antidepressant treatment ⓘ |
| developedBy | Sanofi-Aventis NERFINISHED ⓘ |
| developedInCountry | France NERFINISHED ⓘ |
| drugClass | cannabinoid receptor antagonist ⓘ |
| effectOnBodyWeight | promotes weight loss ⓘ |
| effectOnLipidProfile | improves HDL cholesterol ⓘ |
| effectOnTriglycerides | reduces triglyceride levels ⓘ |
| eliminationRoute |
feces
ⓘ
urine ⓘ |
| formulation | oral tablet ⓘ |
| hasActiveIngredient | rimonabant ⓘ |
| hasGenericName | rimonabant NERFINISHED ⓘ |
| indication |
obesity
ⓘ
weight management ⓘ |
| intendedUse | adjunct to diet and exercise for weight loss ⓘ |
| legalStatus | withdrawn ⓘ |
| mechanismOfAction |
reduces appetite via endocannabinoid system modulation
ⓘ
selective CB1 receptor antagonist ⓘ |
| metabolism | hepatic ⓘ |
| notApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| pregnancyCategory | not recommended in pregnancy ⓘ |
| regulatoryDecisionInUnitedStates | never approved ⓘ |
| regulatoryStatus | withdrawn from market ⓘ |
| routeOfAdministration | oral ⓘ |
| targets | CB1 receptor NERFINISHED ⓘ |
| therapeuticArea |
metabolic disorders
ⓘ
obesity treatment ⓘ |
| tradeNameOf | rimonabant NERFINISHED ⓘ |
| withdrawalReason |
increased risk of depression
ⓘ
increased risk of suicidal ideation ⓘ psychiatric side effects ⓘ |
| withdrawnBy | European Medicines Agency NERFINISHED ⓘ |
| withdrawnInRegion | European Union NERFINISHED ⓘ |
| withdrawnYear | 2008 ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.